Portfolio Manager Factsheet

February 2018

Array BioPharma, Amgen and Vertex Pharmaceuticals were the top positive contributors to performance during the month. Biogen shares were weak due to the unexpected upsizing of its Phase 3 trial of aducanumab in Alzheimer’s disease.

Read more »

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.